公开(公告)号：US20240360187A1

公开(公告)日：2024-10-31

申请号：US18545392

申请日：2023-12-19

Applicant: UNIVERSITÄT BERN

Inventor： Achim STOCKER

IPC: C07K14/47 ,  A61K9/14 ,  A61K9/51 ,  A61K38/00 ,  A61K38/17 ,  A61K47/50 ,  A61P3/02 ,  A61P19/02 ,  A61P21/00 ,  A61P25/14 ,  A61P29/00 ,  B82Y5/00 ,  B82Y40/00

CPC classification number: C07K14/47 ,  A61K9/146 ,  A61K9/51 ,  A61K38/1709 ,  A61K47/50 ,  A61P3/02 ,  A61P19/02 ,  A61P21/00 ,  A61P25/14 ,  A61P29/00 ,  B82Y5/00 ,  B82Y40/00 ,  A61K38/00

Abstract: The present invention relates to a nanosphere comprising an equal number of a human SEC14-like protein and a cognate ligand of said SEC14-like protein as well as to methods of producing the same and uses of said nanospheres.

公开(公告)号：US20240355416A1

公开(公告)日：2024-10-24

申请号：US18753994

申请日：2024-06-25

Applicant: Scipher Medicine Corporation

Inventor： Susan GHIASSIAN ,  Theodore R. MELLORS ,  Marc SANTOLINI ,  Asher AMELI ,  Nancy SCHOENBRUNNER ,  Viatcheslav R. AKMAEV ,  Keith J. JOHNSON

IPC: G16B20/20 ,  A61K38/17 ,  A61P19/02 ,  A61P37/06 ,  C07K16/24 ,  G16B40/00 ,  G16H10/60 ,  G16H20/10 ,  G16H50/20 ,  G16H50/70

CPC classification number: G16B20/20 ,  A61K38/1793 ,  A61P19/02 ,  A61P37/06 ,  C07K16/241 ,  G16B40/00 ,  G16H10/60 ,  G16H20/10 ,  G16H50/20 ,  G16H50/70 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/76

Abstract: Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising administering an alternative to anti-TNF therapy to subjects who have been determined to be non-responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.

公开(公告)号：US20240325389A1

公开(公告)日：2024-10-03

申请号：US17907324

申请日：2021-03-26

Applicant: UNIVERSITÉ PARIS CITÉ ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Inventor： Jean-Philippe HERBEUVAL ,  Benoit SCHNEIDER ,  Nassima BEKKADOUR ,  Vincent BAUDOUIN

IPC: A61K31/506 ,  A61K31/404 ,  A61K31/4409 ,  A61K31/4439 ,  A61K45/06 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  A61P31/18 ,  A61P37/06

CPC classification number: A61K31/506 ,  A61K31/404 ,  A61K31/4409 ,  A61K31/4439 ,  A61K45/06 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  A61P31/18 ,  A61P37/06

Abstract: The present invention relates to an inhibitor of the ROCK-PDK1 protein kinase complex for use thereof as an anti-inflammatory and anti-interferon agent. The present invention also relates to a pharmaceutical composition comprising an inhibitor of the ROCK-PDK1 protein kinase complex as active principle and at least one pharmaceutically acceptable excipient and/or carrier and/or a diluent and/or a pharmaceutically acceptable vehicle. The present invention also relates to the use of said one pharmaceutical composition in the prevention and/or the treatment of inflammatory diseases, viral and/or bacterial infections and autoimmune diseases.

公开(公告)号：US20240285604A1

公开(公告)日：2024-08-29

申请号：US18633272

申请日：2024-04-11

Applicant: Monte Rosa Therapeutics, Inc.

Inventor： Laura Ann McAllister ,  Elisa Liardo ,  Andreas Ritzen ,  Vladas Oleinikovas ,  Xavier Lucas Cabré ,  Bernhard Fasching ,  Lorenzo Delarue Bizzini ,  Mathieu Lesieur

IPC: A61K31/4545 ,  A61P1/04 ,  A61P19/02 ,  A61P37/06 ,  C07D401/10

CPC classification number: A61K31/4545 ,  A61P1/04 ,  A61P19/02 ,  A61P37/06 ,  C07D401/10

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having an inflammatory or autoimmune disorder.

公开(公告)号：US12071478B2

公开(公告)日：2024-08-27

申请号：US16331171

申请日：2017-09-07

Applicant: Daiichi Sankyo Company, Limited

Inventor： Ryuta Mukasa ,  Kensuke Nakamura ,  Sumie Muramatsu ,  Naoyuki Makita

IPC: A61P21/00 ,  A61K31/56 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09 ,  A61K35/12

CPC classification number: C07K16/2803 ,  A61K31/56 ,  A61K39/0008 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09 ,  A61K2035/122 ,  A61K2039/505 ,  A61K2039/577 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided are methods for treatment or prevention of an autoimmune disease that comprise administering a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.

公开(公告)号：US12048750B2

公开(公告)日：2024-07-30

申请号：US17888072

申请日：2022-08-15

Applicant: Blaze Bioscience, Inc.

Inventor： Stacey J. Hansen ,  Claudia Jochheim ,  Dennis M. Miller ,  Natalie Winblade Nairn ,  Julia E. Novak ,  Mark R. Stroud ,  Valorie R. Wiss ,  Kelly Byrnes-Blake ,  Scott Presnell

IPC: A61K38/00 ,  A61B5/00 ,  A61B6/00 ,  A61B6/03 ,  A61B6/40 ,  A61K47/64 ,  A61K47/65 ,  A61K49/00 ,  A61K51/08 ,  A61P13/12 ,  A61P19/02 ,  C07K14/435 ,  C07K14/47 ,  C07K16/24 ,  A61B5/055 ,  A61B8/08

CPC classification number: A61K47/6415 ,  A61B5/0071 ,  A61B6/037 ,  A61B6/4057 ,  A61B6/481 ,  A61K47/65 ,  A61K49/0056 ,  A61K49/0058 ,  A61K51/08 ,  A61P13/12 ,  A61P19/02 ,  C07K14/43518 ,  C07K14/43522 ,  C07K14/4726 ,  C07K16/244 ,  C07K16/248 ,  A61B5/055 ,  A61B8/481 ,  A61B2505/05 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/50

Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

公开(公告)号：US20240238376A1

公开(公告)日：2024-07-18

申请号：US18562108

申请日：2022-05-23

Applicant: Novartis AG

Inventor： Matthias Klaus SCHIEKER ,  Celeste SCOTTI

IPC: A61K38/18 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61P19/02 ,  C07K16/24

CPC classification number: A61K38/1891 ,  A61K9/0019 ,  A61K39/3955 ,  A61P19/02 ,  C07K16/245 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/76

Abstract: Provided herein are methods and dosage regimens for the treatment of osteoarthritis (e.g., knee osteoarthritis). These methods and dosage regimens include intra-articular injections of Compound 1 alone, or in combination with an anti-inflammatory antibody (e.g., an anti-IL-10 antibody).

公开(公告)号：US20240209317A1

公开(公告)日：2024-06-27

申请号：US18556609

申请日：2022-04-22

Applicant: Consorcio Regenero S.A.

Inventor： Maroun KHOURY ,  Francisca ALCAYAGA ,  Aliosha FIGUEROA

IPC: C12N5/077 ,  A61K9/50 ,  A61K31/7105 ,  A61K35/51 ,  A61P19/02 ,  A61P37/06 ,  C12N15/113

CPC classification number: C12N5/0652 ,  A61K9/5068 ,  A61K31/7105 ,  A61K35/51 ,  A61P19/02 ,  A61P37/06 ,  C12N15/113 ,  C12N2310/141

Abstract: Composition enriched in extracellular vesicles (EVs) of umbilical cord mesenchymal cells, with specific markers and miRNAs, where this composition is useful in the treatment of osteoarticular and autoimmune diseases. Specifically, an enriched composition in extracellular vesicles (EVs) of umbilical cord mesenchymal cells is protected, which consists of a set of EVs containing the miRNAs: hsa-miR-6126, hsa-miR-149-3p and hsa-miR-6780b-5p, among the 10 most abundant miRNAs, and additionally contain at least 5 of the following miRNAs: hsa-miR-574-5p, hsa-miR-6131, hsa-miR-6741-5p, hsa-miR-21-5p, hsa-miR-1290, hsa-miR-4530, hsa-miR-2861, hsa-miR-6088, hsa-miR-1307-5p, and/or hsa-miR-6782-5p, and have surface markers CD63, CD81, and CD9; and a medium or vehicle free of animal components and proteins, with an osmolality of between 250 and 310 mOsmol/L and a pH between 6.0 and 8.0. Method of obtaining the composition and its use in the treatment of osteoarticular and autoimmune diseases.

公开(公告)号：US20240182469A1

公开(公告)日：2024-06-06

申请号：US18488871

申请日：2023-10-17

Applicant: Sanofi

Inventor： Dirk Gretzke ,  Olaf Ritzeler ,  Uwe Heinelt ,  Volkmar Wehner ,  Friedemann Schmidt

IPC: C07D471/04 ,  A61K31/437 ,  A61P19/02

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61P19/02

Abstract: The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

公开(公告)号：US11998640B2

公开(公告)日：2024-06-04

申请号：US17675643

申请日：2022-02-18

Applicant: PARK THERAPEUTICS, INC. ,  ENTERIS BIOPHARMA, INC

Inventor： James P. Gilligan ,  George R. Maurer ,  Aniruddha M. Railkar ,  Phillip Bauer ,  Thomas A. Daggs ,  Paul P. Shields

IPC: A61K9/28 ,  A61K9/20 ,  A61K38/23 ,  A61P19/02 ,  A61P19/10

CPC classification number: A61K9/2886 ,  A61K9/2018 ,  A61K9/2081 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2893 ,  A61K38/23 ,  A61P19/02 ,  A61P19/10 ,  A61K9/2095

Abstract: Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.